Related Experiment Video
Updated: Sep 17, 2025
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Paxlovid for the treatment of severe or critical COVID-19 in children
Linjuan Xiang1,2, Qun Wang1,2, Yanwen Xu1,2
1Department of Infectious Disease, Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Background:
Paxlovid, known for its efficacy against SARS-CoV-2, is currently limited in its use for treating pediatric COVID-19, particularly in severe or critical cases.
Methods:
We conducted a study within a single-center, prospective cohort of 450 children diagnosed with COVID-19 between December 2022 and May 2023. This study included 30 pediatric patients who received Paxlovid and 60 matched controls who did not, based on factors such as age, disease severity, and underlying health conditions. Safety was assessed through the incidence of adverse events, and laboratory parameters. The time to clinical symptom improvement was the main efficacy outcome. Moreover, we calculated the AUC0 - 12 h of Nirmatrelvir of the Paxlovid patients.
Results:
Adverse events occurred in 16.7% of both groups, with no serious events reported. The Paxlovid group showed a significantly shorter time to viral clearance, fever resolution, and symptom recovery compared to controls (4.9 vs. 11.0 days, P = 0.01; 11.2 vs. 16.4 days, P = 0.01; 4.6 vs. 17.6 days, P < 0.01). This effect was most noticeable in children with underlying conditions or those treated early. No significant differences were observed in ICU transfers or mortality (P > 0.05). The AUC₀-₁₂h of Nirmatrelvir did not significantly alter treatment outcomes.
Conclusion:
Our findings suggest that Paxlovid may be a safe and effective option for treating severe or critical COVID-19 in children.
More Related Videos
11:27A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
Published on: April 7, 2023
05:46A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:23Acute Respiratory Failure-IV
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include: